FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3098715168> ?p ?o ?g. }

• W3098715168 endingPage "35" @default.
• W3098715168 startingPage "35" @default.
• W3098715168 abstract "There is ongoing controversy about the adverse events of finasteride, a drug used in the management of alopecia and benign prostatic hyperplasia (BPH). In 2012, reports started emerging on men who had used finasteride and either attempted or completed suicide.To investigate the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with finasteride use.This pharmacovigilance case-noncase study used disproportionality analysis (case-noncase design) to detect signals of adverse reaction of interest reported with finasteride in VigiBase, the World Health Organization's global database of individual case safety reports. To explore the strength of association, the reporting odds ratio (ROR), a surrogate measure of association used in disproportionality analysis, was used. Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (≤45 and >45 years); comparing finasteride signals with those of drugs with different mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochloride for BPH); comparing finasteride with a drug with a similar mechanism of action and adverse event profile (dutasteride); and comparing reports of suicidality before and after 2012. Data were obtained in June 2019 and analyzed from January 25 to February 28, 2020.Reported finasteride use.Suicidality and psychological adverse events.VigiBase contained 356 reports of suicidality and 2926 reports of psychological adverse events (total of 3282 adverse events of interest) in finasteride users (3206 male [98.9%]; 615 of 868 [70.9%] with data available aged 18-44 years). A significant disproportionality signal for suicidality (ROR, 1.63; 95% CI, 1.47-1.81) and psychological adverse events (ROR, 4.33; 95% CI, 4.17-4.49) in finasteride was identified. In sensitivity analyses, younger patients (ROR, 3.47; 95% CI, 2.90-4.15) and those with alopecia (ROR, 2.06; 95% CI, 1.81-2.34) had significant disproportionality signals for increased suicidality; such signals were not detected in older patients with BPH. Sensitivity analyses also showed that the reports of these adverse events significantly increased after 2012 (ROR, 2.13; 95% CI, 1.91-2.39).In this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia. The sensitivity analyses suggest that these disproportional signals of adverse events may be due to stimulated reporting and/or younger patients being more vulnerable to finasteride's adverse effects." @default.
• W3098715168 created "2020-11-23" @default.
• W3098715168 creator A5045639743 @default.
• W3098715168 creator A5049453499 @default.
• W3098715168 creator A5061386047 @default.
• W3098715168 creator A5077545940 @default.
• W3098715168 creator A5077645478 @default.
• W3098715168 creator A5090804678 @default.
• W3098715168 creator A5091838080 @default.
• W3098715168 date "2021-01-01" @default.
• W3098715168 modified "2023-10-16" @default.
• W3098715168 title "Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride" @default.
• W3098715168 cites W1592450921 @default.
• W3098715168 cites W1956979632 @default.
• W3098715168 cites W1980755816 @default.
• W3098715168 cites W1991993840 @default.
• W3098715168 cites W2005687876 @default.
• W3098715168 cites W2018377518 @default.
• W3098715168 cites W2020105514 @default.
• W3098715168 cites W2039408383 @default.
• W3098715168 cites W2039594635 @default.
• W3098715168 cites W2051592657 @default.
• W3098715168 cites W2073815848 @default.
• W3098715168 cites W2074289946 @default.
• W3098715168 cites W2086049425 @default.
• W3098715168 cites W2088026293 @default.
• W3098715168 cites W2098897740 @default.
• W3098715168 cites W2107337149 @default.
• W3098715168 cites W2127483997 @default.
• W3098715168 cites W2138375163 @default.
• W3098715168 cites W2140742150 @default.
• W3098715168 cites W2171649714 @default.
• W3098715168 cites W2472705372 @default.
• W3098715168 cites W2494949166 @default.
• W3098715168 cites W2600604755 @default.
• W3098715168 cites W2775074569 @default.
• W3098715168 cites W2790815880 @default.
• W3098715168 cites W2889284654 @default.
• W3098715168 cites W2923783260 @default.
• W3098715168 cites W2926237972 @default.
• W3098715168 cites W2976280418 @default.
• W3098715168 cites W3000186757 @default.
• W3098715168 cites W3007146898 @default.
• W3098715168 cites W3011183895 @default.
• W3098715168 cites W4230615589 @default.
• W3098715168 cites W4235986330 @default.
• W3098715168 cites W4251107853 @default.
• W3098715168 cites W4297900878 @default.
• W3098715168 cites W1501708474 @default.
• W3098715168 doi "https://doi.org/10.1001/jamadermatol.2020.3385" @default.
• W3098715168 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7658800" @default.
• W3098715168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33175100" @default.
• W3098715168 hasPublicationYear "2021" @default.
• W3098715168 type Work @default.
• W3098715168 sameAs 3098715168 @default.
• W3098715168 citedByCount "49" @default.
• W3098715168 countsByYear W30987151682020 @default.
• W3098715168 countsByYear W30987151682021 @default.
• W3098715168 countsByYear W30987151682022 @default.
• W3098715168 countsByYear W30987151682023 @default.
• W3098715168 crossrefType "journal-article" @default.
• W3098715168 hasAuthorship W3098715168A5045639743 @default.
• W3098715168 hasAuthorship W3098715168A5049453499 @default.
• W3098715168 hasAuthorship W3098715168A5061386047 @default.
• W3098715168 hasAuthorship W3098715168A5077545940 @default.
• W3098715168 hasAuthorship W3098715168A5077645478 @default.
• W3098715168 hasAuthorship W3098715168A5090804678 @default.
• W3098715168 hasAuthorship W3098715168A5091838080 @default.
• W3098715168 hasBestOaLocation W30987151682 @default.
• W3098715168 hasConcept C118552586 @default.
• W3098715168 hasConcept C121608353 @default.
• W3098715168 hasConcept C126322002 @default.
• W3098715168 hasConcept C16005928 @default.
• W3098715168 hasConcept C197934379 @default.
• W3098715168 hasConcept C2775874879 @default.
• W3098715168 hasConcept C2776235491 @default.
• W3098715168 hasConcept C2777562237 @default.
• W3098715168 hasConcept C2778515351 @default.
• W3098715168 hasConcept C2778878792 @default.
• W3098715168 hasConcept C2780192828 @default.
• W3098715168 hasConcept C2780542891 @default.
• W3098715168 hasConcept C2908979026 @default.
• W3098715168 hasConcept C558461103 @default.
• W3098715168 hasConcept C57658597 @default.
• W3098715168 hasConcept C71924100 @default.
• W3098715168 hasConceptScore W3098715168C118552586 @default.
• W3098715168 hasConceptScore W3098715168C121608353 @default.
• W3098715168 hasConceptScore W3098715168C126322002 @default.
• W3098715168 hasConceptScore W3098715168C16005928 @default.
• W3098715168 hasConceptScore W3098715168C197934379 @default.
• W3098715168 hasConceptScore W3098715168C2775874879 @default.
• W3098715168 hasConceptScore W3098715168C2776235491 @default.
• W3098715168 hasConceptScore W3098715168C2777562237 @default.
• W3098715168 hasConceptScore W3098715168C2778515351 @default.
• W3098715168 hasConceptScore W3098715168C2778878792 @default.
• W3098715168 hasConceptScore W3098715168C2780192828 @default.
• W3098715168 hasConceptScore W3098715168C2780542891 @default.
• W3098715168 hasConceptScore W3098715168C2908979026 @default.

• next